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Abstract 
Objective: Silent myocardial ischemia is thought to be associated with worse cardiovascular 
outcomes due to a lack of perception of pain cues that initiate treatment seeking. Negative affect 
(NA) has been associated with increased pain reporting and positive affect (PA) with decreased 
pain reporting, but these psychological factors have not be examined within the context of 
myocardial ischemia. This study evaluated the associations between PA, NA and chest pain 
reporting in patients with and without ischemia during exercise testing.  
Methods: 246 patients referred for myocardial perfusion single photon emission computed 
tomography exercise stress testing completed the PANAS-X, a measure of PA and NA. Presence 
of chest pain and myocardial ischemia were evaluated using standardized protocols. 
Results: Logistic regression analyses revealed that for every 1 point increase in NA, there was a 
13% higher chance for ischemic patients (OR=1.13; 95%CI=1.02-1.26) and an 11% higher 
chance in non-ischemic patients (OR=1.11; 95%CI=1.03-1.19) to report chest pain. A significant 
interaction of PA and NA on chest pain reporting (β=0.02; 95% Cl=0.002-0.031) was also 
observed; non-ischemic patients with high NA and PA reported more chest pain (57%) versus 
patients with low NA and PA (13%), with high NA and low PA (17%), and with high PA and low 
NA (7%). 
Conclusions: Patients who experience higher NA are more likely to report experiencing chest 
pain. Patients without ischemia are also more likely to report chest pain. Results suggest that 
reporting high levels of positive and negative affect may influence the experience and/or reporting 
of chest pain. 
 
 
Keywords: positive affect, negative affect, silent ischemia, chest pain, coronary heart disease 
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Abbreviations: AHA = American Heart Association; CAD = coronary artery disease; CI = 
Confidence interval; CVD = cardiovascular disease; ECG = Electrocardiographic; GLM = 
Generalized linear model; HR = Hazard ratio; IHD = ischemic heart disease; MHI = Montreal Heart 
Institute; MHCL = Multicomponent Health Locus of Control MOSMI = Cross-sectional 
Mechanisms and Longitudinal Outcomes of Silent Myocardial Ischemia study; NA = negative 
affect; OR = Odd ratio PA = positive affect; PANAS-X = Positive and Negative Affect Schedule-
expanded version; SPECT = single photon emission computed tomography  
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Introduction 
According to the World Health Organization, cardiovascular disease (CVD) is the number 
one cause of mortality worldwide (1). Of all forms of CVD, coronary artery disease (CAD) is 
responsible for the majority of morbidity and mortality (2). The American Heart Association (AHA) 
reported that 15.5 million persons in the United States have CHD, including 8.2 million with angina 
pectoris (2). Myocardial ischemia is a condition triggered by an imbalance between myocardial 
oxygen supply and demand (3, 4), and is a key predictor of future CVD events and outcomes (5-
7). 
Importantly, myocardial ischemia may or may not be accompanied by chest pain (3, 4). 
However, most ischemic episodes (i.e., 70%-75%) occur in the absence of chest pain, a condition 
known as “silent ischemia” (4, 8-10). The occurrence and detection of chest pain during an 
ischemic episode may be critical for self-initiation of treatment (e.g., taking vasodilators) or timely 
presentation to the emergency department (ED), both of which may reduce cardiac morbidity and 
mortality (11). Delays in treatments or presentation for assessment are likely reasons why patients 
with silent ischemia are at increased risk for cardiac events and mortality (8, 10). Accurate chest 
pain perception during episodes of ischemia may be even more critical for patients with previously 
undiagnosed CAD, due to lack of awareness of a pre-existing cardiac condition. The AHA 
estimates that approximately two-thirds of women and half of men who died suddenly of CAD had 
no prior CAD history (2). Therefore, determining factors associated with accurate chest pain 
perception in the context of ischemia represents an important clinical research goal. In addition 
to the links between CVD outcomes and ischemia, there is also a documented link between 
psychiatric disorders and CVD development and outcomes (12, 13). Negative affect (e.g., 
depressed mood and anxiety) is a strong predictor of future CVD events and outcomes (12, 13), 
and has been linked to clinical markers of CVD such as exercise induced ischemia (14, 15), as 
well as, poor pain perception (16, 17).  
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Pain perception is a multidimensional experience involving physical pain sensitivity and 
accurate interpretation of pain sensations (18). Accurate pain perception may be influenced by 
negative and positive affect. Collectively, the general affect-pain literature suggests that negative 
affect (NA: e.g., anxiety, anger) may increase and positive affect (PA: e.g., happiness, joy) may 
decrease pain perception or sensitivity (19).  For example, patients exposed to high situational 
anxiety tend to report higher levels of pain intensity in response to the cold pressor test (20), with 
trait anger positively correlated with pain perception (21). Also, patients with higher levels of anger 
and frustration are more likely to experience cancer-related pain at greater intensity levels and for 
longer durations compared to patients with lower levels of anger and frustration (22). Previous 
studies have demonstrated that measures of NA, such as depression, are generally associated 
with greater pain symptom reporting in patients with and without CVD (16, 17), as well as higher 
reported pain intensity in post-surgical patients (23). However, higher general NA has also been 
shown to predict the presence of exercise-induced angina (24). Anxiety, another measure of NA, 
has been linked to higher reports of chest pain among cardiac and non-cardiac populations (25, 
26). In contrast, patients with silent ischemia (no chest pain) appear to have lower levels of 
depression and anxiety (27).  
Little is known as to whether negative affect can influence the reporting and presence of 
chest pain when myocardial ischemia is also present, nor whether negative affect can lead to 
increases in chest pain reporting when there is no other physiological symptom of disease such 
as myocardial ischemia. Untangling whether negative affect can lead to the reporting of chest 
pain which may be ‘phantom pain’, or psychosomatic in nature, is clinically important, as accurate 
pain perception may be critical for timely and potentially life-saving intervention (20, 28-31).   
Studies in chronic disease populations (e.g., rheumatoid arthritis, fibromyalgia and sickle-
cell disease), have shown that higher levels of PA are associated with reduced pain perception 
(29-31), lower pain intensity (29, 30), and reduced perceptions of pain intensity (19, 31). In the 
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context of CVD, increased PA has been linked with a reduced risk of stroke, decreased hospital 
readmission after a cardiac events and lower mortality in cardiac patients (32-34). However, there 
is minimal information on the role of positive affect (PA) on chest pain perception in the context 
of CVD.  
In the majority of the CVD literature, studies have focused on either NA or PA and few 
have assessed both in the same study. This limitation is notable given that the dynamic model of 
affect suggests that in a chronic, stressful situation (e.g., chronic pain), a high level of NA could 
suppress the capacity of PA to compensate by becoming the only information that is processed 
by the brain (35). This model also suggests that under normal circumstances, PA and NA are 
processed by distinct neural process and they can be manipulated independently (35). Thus 
examining the role of NA and PA concurrently is important, particularly in the context of detecting 
chest pain and ischemia, to examine if NA or PA play a buffering role on chest pain reporting and 
whether this could mask clinically important factors such as ischemia and chest pain. 
Thus, the objective of the present study was to assess associations between PA and NA 
and chest pain perception among patients who presented for diagnostic exercise stress testing. 
We hypothesized that patients with higher levels of NA would be more likely to report experiencing 
chest pain during exercise compared to patients with lower levels of NA, and that patients with 
higher levels of PA would be less likely to report chest pain during exercise compared to patients 
with lower levels of PA, particularly among patients in whom ischemia is not induced during 
exercise testing. 
 
Methods 
Participants 
This study was a sub-study of the Cross-sectional Mechanisms and Longitudinal 
Outcomes of Silent Myocardial Ischemia (MOSMI) Study, a prospective study designed to 
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examine the impact of blood pressure and pain on myocardial ischemia.  Participants presenting 
to the Montreal Heart Institute (MHI) for single photon emission computed tomography (SPECT) 
exercise stress testing were recruited between May 2005 and December 2006. Exclusion criteria 
were: 1) already participating in another study at the MHI; 2) pregnant or nursing; 3) taking non-
steroid anti-inflammatory drugs in the 7 days prior to stress-test; 4) taking an analgesic the day of 
the stress test; 5) suffering from a major medical condition other than CAD (e.g., cancer, AIDS); 
6) suffering from any severe mental disorder (e.g., schizophrenia) or evidence of current 
substance abuse; 7) less than 18 years old; 8) unable to speak/understand English or French or 
9) suffering from a pain disorder other than angina. Our definition of a pain disorder was based 
on the DSM-IV definition of pain disorder which included chronic pain in one or more areas thought 
to have psychogenic origin and related neurologic conditions (phantom pain, hyperalgesia, 
hypoalgesia), but did not include musculoskeletal pain or back/pelvic pain. 
  
A total of 2138 participants presented to the Nuclear Medicine Department of the MHI for 
an exercise stress test prescribed by their doctor during the recruitment period, of which 1174 
patients (55%) were approached to participate. Due to a lack of personnel, some patients were 
not approached if they presented simultaneously for their stress test. As shown in Figure 1, 124 
patients were excluded, resulting in 1050 eligible participants. Only 143 participants declined to 
participate, yielding a final sample of 907 participants (86% participation rate). Late introduction 
of this sub-study in the larger MOSMI study (after the 582th patient), missing data, and participant 
attrition, left a final participating sample of 246 participants for this sub-study. There were no 
significant differences between this subgroup and the remaining MOSMI sample (i.e., the 661 
individuals not included in this sub-study) in demographic or clinical data, i.e., age, sex, presence 
of clinical pain, ischemia, silent ischemia or previous cardiac diseases.  The MHI scientific and 
ethics committees approved this study, and all patients provided written, informed consent. 
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Procedure 
Patients were informed of the study procedures and a trained clinical research assistant 
obtained informed consent. Eligible and consenting patients underwent a standard treadmill 
exercise stress test (modified Bruce protocol). The stress test was followed by SPECT imaging 
under the supervision of a nuclear medicine physician according to standard procedure (36, 37). 
Patients were maintained on their usual medication throughout the protocol. Participants were 
then asked to complete a socio-demographic and medical history questionnaire, followed by the 
self-report Positive and Negative Affect Schedule-expanded version (PANAS-X) (38). 
 
Measures 
Positive and Negative Affect Schedule- Expanded. PA and NA were evaluated using the 
PANAS-X, which measures state and trait constructs of positive and negative affect 
experienced in the last few weeks (38). The PANAS has 60 items, rated on a scale from 1 to 5 
(1 = very slightly or not at all; 5 = extremely) to yield overall PA and NA scores as well as scores 
on subscales of negative (Fear, Sadness, Guilt, Hostility, Shyness, Fatigue) and positive 
(Surprise, Joviality, Self-Assurance, Attentiveness, and Serenity) affect. NA was calculated by 
summing the scores for the following constructs: afraid, scared, nervous, jittery, guilty, 
ashamed, irritable, hostile, upset and distressed. PA was calculated as the sum of: active, alert, 
attentive, enthusiastic, excited, inspired, interested, proud, strong and determined. This is in line 
with the PANAS-X scoring manual (38). Conceptually, the PA and NA scales are independent 
dimensions, such that patients can score anywhere along the continuum of each scale (i.e., 
patients can score high on both PA and NA) (38, 39). The mean of each scale is calculated for 
each patient to determine overall positive and negative affect levels. Internal reliability ranges 
from .85 to .90 for the NA scale and from .83 to .90 for the PA scale (38). The PANAS-X 
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subscales have demonstrated excellent psychometric properties, including excellent convergent 
validity (r = .85 to .91) with the Profile of Mood States and good and moderate correlations, 
respectively, for the PA and NA subscales of the Global Mood Scale (PA = 0.79 and NA = 0.56) 
(38, 40, 41). Both PA and NA scales have good stability over 2 months (test-retest correlations 
of 0.71 and 0.70, respectively) (38). A standard forward-backward translation of the PANAS-X 
was performed to translate the PANAS-X into French. The internal reliability ranges were from 
.81 to .86 for the individual constructs of the NA scale and from .81 to .89 for the individual 
constructs of the PA scale for the whole sample; specifically the internal reliability coefficients 
were .87 for PA and .81 for NA both English version) and .87 for PA and .86 for NA for the 
translated French version of the PANAS-X. 
Chest pain assessment. Chest pain perception during treadmill exercise stress testing 
was evaluated by a trained exercise stress test technician and overseen by a cardiologist, who 
asked patients to self-report the presence and intensity of any chest pain occurring during the test 
using a 10-point rating scale (42). Patients with a score of greater than 0 were considered to be 
experiencing chest pain. Ultimately, the cardiologist determined whether the pain was related to 
an underlying cardiac or non-cardiac condition (e.g., back pain) according to standard procedure 
(43). Patients who had confirmed exercise-induced chest pain were classified as having angina-
related chest pain; those without were classified as having no chest pain. 
Ischemia assessment. SPECT assessments of reversible myocardial perfusion defects 
at peak exercise were evaluated by experienced nuclear medicine physicians according to the 
standard procedure (36, 37) using an Irix-3 model camera (Philips, Cleveland, Ohio). The 
objective of the visual assessment of SPECT myocardial perfusion images was to determine if 
there were defects on stress images and whether these defects were reversible on the rest 
SPECT images (44). A total of 21 segments were analysed for each patient, with at least 2 
reversible defects were needed in order to classify the patient as having ischemia. Patients were 
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determined to have had silent ischemia if they had evidence of ischemia on the SPECT scan but 
reported no chest pain, discomfort or other angina equivalent during their treadmill test (44). 
 
Statistical analyses 
Primary analyses. Baseline variables are presented as means ± SD and proportions (n) 
for continuous and categorical variables, respectively. General Linear Models were used to 
determine baseline variable differences as a function of group. These groups were: 1) No Chest 
Pain; No Ischemia; 2) Silent Ischemia; 3) Chest Pain; No Ischemia; 4) Ischemia with Chest Pain. 
Correlations (or chi-square analyses, where appropriate) were used to determine relationships 
between NA, PA, Ischemia and Chest Pain. A series of logistic regressions analyses adjusting for 
age, sex, total exercise METS, prescription of anti-ischemic medications, and analgesic 
medication use (not initially reported during recruitment) on the day of the test were used to 
assess main and interaction effects of PA and NA on chest pain perception. Identical analyses 
also investigated the 3-way interaction between PA, NA and ischemia, with further examination 
of the interaction between PA and NA completed for patients with and without ischemia, 
separately. For the analyses PA and NA were used continuously. Estimates from the multiple 
imputation analysis for the main and interaction effects are reported in tables. Corresponding 
odds-ratios for the main effects are reported in the text. As per previous examples (45), upper 
and lower quartiles of NA and PA were used to graphically represent the nature of any statistically 
significant interactions.  All covariates were determined a-priori based on previously established 
associations with the dependent variables (14). 
 Imputation of missing data. Using Rubin's rules (46) our missing data analysis 
procedures used multiple imputation (47) with missing at random (MAR) assumptions. There were 
no systematic differences in the amount of missing data across groups. Using the PROC MI 
method of multiple multivariate imputation in SAS, we independently analyzed 20 copies of the 
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data. PROC MIANALYZE was used according to Harrell’s guidelines (48). Details of the amount 
of missing data per variables are included in Table 1. All analyses were 2-tailed and significance 
was set at p < .05. All statistical analyses were conducted using SAS V. 9.3 (SAS Institute, Cary, 
NC). 
 
Results 
Participant characteristics 
Patients were 65% male with a mean age of 59.9 (SD= 10.57) years (range 27 to 83 years 
old). 95% were White, 73% were cohabitating with a partner, and the mean number of years of 
education was 13.7 (SD = 4.1) years. The participants’ mean body mass index (BMI) was 27.8 
(SD = 4.5) kg/m2 (overweight range) and 13% were current smokers. A total of 24% of the sample 
had a previous myocardial infarction, 61% were hypertensive, and 14% had diabetes. 
Comparisons of socio-demographics and clinical characteristics as a function of chest pain and 
ischemia status are presented in Tables 1 and 2. The analyses showed significant differences 
between the two ischemia groups (with and without  chest pain) and the no ischemia groups (with 
and without chest pain) on BMI, hypertension, cholesterol, any coronary heart disease, previous 
myocardial infarction, and diabetes, with higher prevalence seen in the ischemia groups. Similarly, 
the analyses also showed that the ischemia groups were prescribed more medication than the no 
ischemia groups. 
Among the 246 patients, 78 (31.7%) patients developed exercise-induced ischemia. 
Exercise-induced ischemia with chest pain was observed in 23 (9.35%) patients, 55 (22.4%) had 
ischemia without chest pain (silent ischemia), 23 (9.35%) no ischemia but nonetheless reported 
chest pain. Patients with inducible ischemia had more often chest pain during exercise (29.5% vs 
13.7%, Χ2 = 8.74, p = .003)) and a higher pain severity score (1.19 ± 2.43 vs. 0.72 ± 1.92) 
compared to patients without ischemia. Eight / 85 women (9.1%) developed ischemia, compared 
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to 71/163 (43.6%) men (p < .001), whereas no sex differences were found in reported chest pain 
(20.0% (M) vs 17.7% (W), p = .65). 
 
PA, NA, and the relationships to chest pain and ischemia. 
The mean PA and NA scores were 29.3 ± 6.9 and 17.2 ± 6.2 respectively. There was a 
negative correlation between NA and PA (r = -.34, p < .001), indicating that patients with higher 
negative affect reported lower levels of positive affect. Furthermore, chest pain was correlated 
with NA (r = .23, p < .001) but not PA (r = .04, p = .55). Ischemia was not associated with NA (r 
= -.01, p = .88) nor PA (r = -.04, p = .51). Analysis of differences in NA and PA by group (no 
ischemia, no chest pain; silent ischemia; chest pain, no ischemia; chest pain and ischemia) 
revealed an effect of group for NA (F = 4.44, p = .004). Post hoc analysis revealed the highest 
levels of NA in the group with chest pain and ischemia, and the lowest NA in the no chest pain 
no ischemia group. These differences are displayed in Table 1. 
 
Regarding exercise stress test characteristics (Table 2), there were no significant main 
effects of group for test duration, Metabolic equivalents (METs), baseline SBP, baseline DBP or 
baseline HR (all p’s > .05). While there were no main effects of group for peak SBP or peak 
DBP, there was a main effect of peak HR (F = 2.75, p = .044). Post-hoc analyses revealed 
patients who experienced ischemia with chest pain or silent ischemia had significantly lower 
peak HR’s compared to patients with no chest pain and no ischemia (both p’s < .05). There 
were no post-hoc differences in peak HR between patients with chest pain but no ischemia and 
patients with no chest pain and no ischemia. There was also a main effect of group for patients 
who achieved their Maximum Predicted Heart Rate (MPHR) (F = 4.65, p = .004). Post-hoc 
analyses revealed that patients with ischemia and chest pain had a lower number of patients 
who did not reach their MPHR compared to patients with no ischemia and no chest pain, and 
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compared to patients who had silent ischemia (p’s < .05). There were no other group 
differences. Unsurprisingly, there also group differences for self-reported chest pain (F = 
119.27, p < .001), where patients with chest pain and no ischemia, and patients with ischemia 
and chest pain had higher self-reported chest pain than the patients with silent ischemia and 
patients with no chest pain and no ischemia (all p’s < .05). 
 
Associations between PA, NA and ischemia on chest pain  
A series of Logistic regressions examined the associations between PA, NA and 
ischemia on chest pain (see Table 3). Across the whole sample, we saw associations between 
PA (OR = 1.01, 95% CIs= 1.00 - 1.02, p = .038)), NA (OR = 1.02, 95% CIs= 1.01 - 1.02, p < 
.001) and ischemia (OR = 1.17, 95% CIs= 1.04 - 1.31, p = .007) on chest pain, which were 
significant having adjusted for age, sex, total exercise METS, prescription of anti-ischemic 
medications, and analgesic medication use. Furthermore, across the whole sample, we also 
saw trends for an interaction between PA and NA (β = -0.001, 95% CIs= -0.00 - 0.00, p = .07), 
after adjusting for covariates, including ischemia. In addition, there was a trend for an interaction 
between PA and ischemia (β = 0.04, 95% CIs= -0.005 – 0.08, p = .079), a significant interaction 
between NA and ischemia (β = 0.07, 95% CIs= 0.01 - 0.13, p = 0.02) and a trend for a 3-way 
interaction between PA, NA and ischemia (β = -0.002, 95% CIs= -0.004 - 0.00, p = 0.069) in the 
association with pain. 
Interrogation of the 3-way interaction was undertaken, stratifying patients by ischemia 
status. As detailed in Table 4, the analysis revealed that in patients with ischemia, there was a 
significant effect of NA (OR=1.13; 95% CIs= 1.02-1.26) but not for PA (OR=1.06; 95% CIs= 
0.96-1.12) for the association between reporting chest pain, indicating that patients with higher 
levels of NA were more likely to report experiencing chest pain during exercise. In the 
interaction model, there was no interaction effect of PA and NA. In patients without ischemia, 
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higher levels of NA were also associated with an increased frequency of reporting chest pain 
during the stress test. As detailed in Table 4, the main effects analysis in patients without 
ischemia mirrored that of the ischemia patients with a statistically significant association 
between for NA (OR= 1.11; 95% CIs= 1.03-1.19) but not PA (OR= 1.07; 95% CIs= 0.99-1.15). 
Among patients without ischemia, there was also a significant interaction between PA and NA 
on chest pain reporting, where patients with higher levels of both NA and PA were more likely to 
report chest pain (β = 0.02; 95% Cls= 0.002-0.03) compared to patients with low levels of NA 
and PA (see Figure 2).  
 
Discussion 
The objective of the present study was to examine relationships between PA/NA and chest 
pain perception in the context of ischemia in patients undergoing exercise stress tests. We 
expected that patients with higher levels of NA would be more likely to report chest pain, and 
patients with higher levels of PA would be less likely to report chest pain, particularly among those 
with ischemia (silent ischemia). Our hypotheses were only partially supported: with higher levels 
of NA being associated with an increased frequency of reporting chest pain in both ischemia and 
non-ischemia patients. However, higher levels of PA alone were not associated with a reduction 
in chest pain reporting; higher NA was associated with an increased chance of chest pain 
reporting, irrespective of ischemic status. Interestingly, we observed an interaction between PA 
and NA on chest pain reporting in the non-ischemic patients only, such that patients with higher 
levels of both PA and NA had a greater probability of reporting chest pain. This suggests that 
patients with overall higher levels of both NA and PA are more likely to report experiencing chest 
pain during exercise stress tests, especially in the absence of ischemia. However, ischemia was 
not associated with NA nor PA. Our study uniquely presents evidence of the interactive and 
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dynamic associations of both NA and PA in the context of ischemia and chest pain reporting, 
particularly the unique association of elevated affect in those who do not have ischemia.  
In terms of the magnitude of our associations, our findings suggest that every 1 point 
increase in NA was associated with a 13% and 11% greater chance of reporting chest pain during 
exercise in patients with and without ischemia, respectively. These results are generally 
consistent with previous reports (24). Previous studies have demonstrated that NA affect 
measures, such as depression, are associated with greater symptom reporting in patients with 
and without CVD (16, 17). Another study demonstrated that higher levels of anxiety and 
depression, evaluated by the Hospital Anxiety and Depression Scale (HADS) , were associated 
with higher reported pain intensity in post-surgical patients (23). Anxiety, another measure of NA, 
has also been linked to higher reports of chest pain among cardiac and non-cardiac populations 
(25, 26). It is though that these relationships may be due to changes in a combination of 
physiological systems such as the autonomic nervous system, coronary vasculature system 
including increased microvascular resistance (26) , as well as possibly due to fears associated 
with having cardiac events (49, 50). Patients with a high level of anxiety have a greater tendency 
to catastrophize somatic symptoms, which has been related to increase pain reporting (51). 
Patients with anxiety may also be hyper-vigilant to chest pain and report more chest pain during 
a stress test (52). Our findings are also consistent with a study reporting that most patients 
seeking emergency care for non-cardiac chest pain report higher levels of NA (e.g., depression 
and history of panic) (49). Similarly, patients with a high level of neuroticism (a personality trait 
where individuals are more likely to experience anger, anxiety, and depression) report more chest 
pain or discomfort than patients with a lower level of neuroticism (17, 53). Though the 
mechanisms linking negative affective states and pain perception have not been fully delineated, 
one possibility is impairments of the endogenous opioid system in the anterior cingulated cortex, 
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which is involved in pain regulation (54). When impaired, this system is associated with a reduced 
ability to modulate negative emotions as well as elevated pain sensitivity (54). 
Contrary to our hypotheses, we did not observe any associations between higher levels 
of PA alone and reduced pain reporting, irrespective of ischemia. Rather, we observed that PA 
was related to increased chest pain reporting, and demonstrated a significant interaction between 
PA and NA and reports of chest pain in non-ischemic patients. In this group, patients with higher 
levels of both PA and NA reported more chest pain compared to other patients. This is particularly 
interesting, given that patients with high NA and low PA did not report the same prevalence of the 
presence of chest pain compared to high NA/high PA patients. A previous study demonstrated 
that patients with higher levels of “emotionality” reported more incongruent lower back pain 
(inappropriate symptomatic complaints or nonorganic physical signs) (55), which parallels our 
findings. Though we did not directly assess “emotionality”, it is possible that scoring high on both 
PA and NA may reflect the same construct. In contrast to our findings, it has been observed that 
anhedonic patients have a tendency to report more somatic symptoms (56). An alternative 
hypothesis is that patients with high levels of PA, including feelings of assertiveness and self-
assurance, could also be displaying proactive health behaviors by reporting that they are 
experiencing chest pain. Others have shown that positive affect is related to internal components 
of the Multicomponent Health Locus of Control (MHLC) (57). However, as we did not assess 
MHLC in our sample this must remain speculative. To our knowledge, this is the first study to 
specifically assess the association between PA and pain reporting in the context of ischemia. 
Though our findings did not support an association, they do add to the extant literature on the 
psychological factors that may (or may not) be involved in chest pain in cardiac patients.  
Results of the present study should be interpreted in light of some limitations. First, patient 
selection was not random and participants were predominantly male and White, so results may 
not generalize to women or a non-White population. Second, though the sex ratio in our study is 
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consistent with that seen in a clinical setting, due to the uneven proportions of men and women 
and low absolute numbers of women, we were not able to examine sex differences in chest pain 
reporting and ischemia as a function of PA and NA. Many studies report that women are more 
likely to exhibit lower pain thresholds, have a lower tolerance to noxious stimuli, and report more 
somatic complaints compared to men (58). Women also describe their chest pain differently than 
men and report greater pain intensity relative to men (59). Although we adjusted for sex in our 
analyses, future studies should aim to examine sex differences in these associations. Also, the 
pain measure used in this study was dichotomous (presence or absence of chest pain). This does 
not allow us to assess potential differences in pain quality as a function of PA or NA. Furthermore, 
it should be noted that this is a population who were undergoing exercise stress testing and, as 
such, individuals with conditions that interfered with their ability to exercise (e.g., severe 
musculoskeletal pain) would have been ineligible for such a test, and our findings should be 
viewed in light of this. One important consideration is the broader role of psychological 
characteristics which may influence chest pain and reporting of chest pain (50, 60).  Furthermore, 
patients with CAD are more likely to under-report their emotional distress compare with patients 
with less severe cardiac condition (61). This may have disproportionally influenced the chest pain 
reported in the ischemia group. Furthermore, patients with CHD (or more severe CHD) may be 
more likely to under-report emotional distress relative to patients with less severe CHD 
symptomology. This disparity could have influenced the NA-PA reporting in the ischemia group, 
and should be considered in light of our findings. 
Despite some limitations, this study also has several important strengths. To our 
knowledge, this study is the first to investigate the relationship between PA and NA and their 
interaction on chest pain reporting among patients with and without ischemia, adding critical new 
information. Second, compared to pain perception studies in general, our sample size is relatively 
large at 246. Though we had uneven proportions of men and women in the study, the percentage 
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of men (65%) in our sample reflects the disproportionately male cardiac population referred for 
an exercise SPECT tests, and is thus highly representative of this population. Third, experienced 
cardiologists conducted the chest pain and ischemia assessments according to standard 
procedures. Fourth, PA and NA was assessed using the PANAS-X, which is an excellent 
assessment of affect with very good psychometric properties.  
Our results indicate that irrespective of ischemia, patients who experience greater levels 
of NA or PA are more likely report experiencing chest pain. However, among patients without 
ischemia, those reporting generally high levels of both NA and PA are also more likely to report 
chest pain. Given that patients with high NA have higher odds to report chest pain, whether or not 
they have ischemia, practitioners should be vigilant if patients exhibit or report symptoms’ of 
negative mood, as this may influence the perception and experience of chest pain among patients 
undergoing diagnostic exercise stress testing, which may impact clinical findings. They should 
also consider that the pain reported in those patients may or may not be related to underlying 
ischemia. (28). Given that both high PA and NA appear to be important, more studies are needed 
to further disentangle the relationship between positive and negative emotions and pain 
perception in the context of ischemic heart disease.   
 
 
   
20 
 
Table 1: Participant sociodemographic characteristics 
N(%) or M ± SD No Chest Pain; 
No Ischemia 
(n=145) 
Silent Ischemia 
(n=55) 
Chest Pain; No 
Ischemia 
(n=23) 
Ischemia with 
Chest Pain 
(n=23) 
N  missing 
data 
 
F/x2 
 
p 
Sociodemographics 
Age 58.3 ± 11 63.7 ± 9.7 a 59.7 ±  11.3 58.7 ± 7 0 3.57 .015 
Sex (% female) 66 (46) 4 (7) a 11 (48) b 4 (17) a,c 0 11.46 <.001 
White 140 (97) 51 (94) 21 (91) 23 (100) 1 .89 .45 
Living with a partner 115 (69) 42 (78) 17 (74) 19 (83) 1 .95 .42 
Years of education 14.1 ± 4.4 13.83 ± 3.7 13.3 ± 3.6 11.4 ± 3.7 a,b 16 2.81 .040 
 
Medical history characteristics 
BMI 27.5 ± 4.7 29.3 ± 3.9 27.6 ± 4.6 29.3 ± 3.8 3 1.32 .27 
Hypertension 77 (53) 39 (72) a 15 (65) 19 (83) a 1 3.91 .009 
Hyperlipidemia 78 (54)  42 (78) a 16 (69) 20 (87) a 1 5.51 .001 
Current smoker 18 (9) 8 (4) 2 (4) 3 (7) 6 3.79 .15 
Former smoker 70 (36) 32 (16) 11 (24) 14 (30) 6 1.56 .46 
Diabetes 15 (10) 7 (16) a 0 b 5 (22) c 1 4.49 .004 
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Cardiac history 
Any CHD 41 (28) 30 (55) a 6 (26)b 15 (65) a,c 9 7.5 <.001 
Previous MI 22 (16) 19 (40) a 4 (20) 10 (48) a,c 21 6.14 <.001 
Previous CABG 12 (9) 5 (11) 1 (5) 6 (32) a,b,c 29 3.25 .023 
Previous PCI 22 (16) 16 (36) a 4 (19) 10 (53) a,c 25 6.20 <.001 
 
Medications 
ACE-inhibitors 19 (13) 13 (24) a 4 (17) 9 (39) a,c 2 3.87 .010 
Beta-blockers 40 (28) 17 (31) 7 (30) 13 (57) a,b,c 2 2.57 .055 
Any Anti Blood 
Pressure 
61 (42) 37 (69) a 10 (43) 18 (78) a,c 2 6.76 <.001 
ARB 16 (11) 13 (24) a 1 (4) b 4 (17) 2 2.56 .055 
Diuretics 16 (11) 8 (15) 9 (4) 4 (17) 2 .81 .49 
Ca-Channel blockers 19 (13) 12 (22) 3 (13) 9 (39) a,c 2 3.86 .010 
Vasodilators 4 (3) 2 (4) 2 (9) 3 (13) a 2 1.99 .12 
Any anti-ischemic 52 (36) 27 (50) 9 (39) 17 (74) a,b,c 2 4.49 .004 
Lipid-lowering 55 (38) 37 (69) a 10 (43) b 16 (70) a 2 6.80 <.001 
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Affect Scale Scores 
Negative Affect (NA) 16.8 ± 5.9 15.6 ± 4.7 19.8 ± 6.7 a,b 20.0 ± 8.7 a,b 2 4.44 .004 
Positive Affect (PA) 29.1 ± 7.0 28.8 ± 6.4 30.6 ± 7.1 28.6 ± 7.8 1 0.41 .74 
Note: BMI, body mass Index; CHD, Coronary heart disease; MI, myocardial infarction; CABG, coronary artery bypass graft surgery; 
PCI, Percutaneous coronary intervention; ACE, angiotensin converting enzyme; ARB, Angiotensin II receptor blockers Ca-channel, 
calcium channel. a indicates significantly different from No Chest Pain; No Ischemia (p < .05); b indicates significantly different from 
Silent Ischemia (p < .05); c indicates significantly different from Chest Pain, No Ischemia Group (p < .05); d indicates significantly 
different from Ischemia with Chest Pain (p < .05) 
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Table 2: Exercise stress test characteristics as related to ischemia and chest pain 
Stress test results 
M ± SD 
No Chest Pain; 
No Ischemia 
(n=145) 
Silent Ischemia 
(n=55) 
Chest Pain; No 
Ischemia 
(n=23) 
Ischemia with 
Chest Pain 
(n=23) 
N  missing 
data 
 
F/x2 
 
P 
Duration (s) 458 ± 108 471 ± 93 456 ± 90 432 ± 90 1 .81 .49 
METS 
(3.5ml/kg/02/min) 
8.24 ± 1.8 8.25 ± 1.7 8.11 ± 1.7 7.46 ± 1.8 0 1.42 .24 
% MPHR 90.74 ± 12.9 87.47 ± 13.3 86.22 ± 12.7 80.30 ± 15.4 a,b 0 4.65 .004 
Baseline SBP (mmHg) 130.65 ± 16.6 133.64 ± 17.2 131.85 ± 17.2 130.46 ± 17.3 2 .44 .72 
Baseline DBP (mmHg) 81.89 ± 10.9 81.07 ± 8.4 81.74 ± 8.1 83.04 ± 12.9 2 .20 .89 
Baseline HR (bpm) 73.62 ± 14.8 71.20 ± 14.9 68.13 ± 9.1 69.46 ± 13.8 2 1.45 .23 
Peak SBP (mmHg) 164.66 ± 27.7 163.74 ± 23 163.13 ± 24.5 159.73 ± 24.7 3 26 .86 
Peak DBP (mmHg) 83.22 ± 11.2 83.29 ± 8.9 83.74 ± 9.7 84.39 ± 13.8 3 .08 .97 
Peak HR (bpm) 137.53 ± 24.7 129.63 ± 21.1 a 129.48 ± 26.3 125.57 ± 28.2 a 3 2.75 .044 
Self-reported Chest 
Pain score (0-10) 
0.10 ± 0.61 0  4.30 ± 2.93 a 4.09 ± 2.92 a 0 119.27 < .001 
Note: METs, Metabolic Equivalent; MPHR, Maximum Predicted Heart Rate; SBP, Systolic blood pressure; DBP, Diastolic blood 
pressure, HR, Heart rate. a indicates significantly different from No Chest Pain; No Ischemia (p < .05); b indicates significantly 
different from Silent Ischemia (p < .05) 
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Table 3: Logistic regressions to examine the association between the presence of pain across the whole sample, and 
examine a 3-way interaction between PA, NA and Ischemia 
 
 Model 1 Model 2 † Model 3 Model 4 † 
β 95% CIs p β 95% CIs p β 95% CIs p β 95% CIs p 
PA 0.007 0.00-0.01 .048 0.01 0.00-0.02 .038 -0.02 -0.05-0.00 .06 -0.03 -0.05--0.00 .02 
NA 0.02 0.01-0.02 <.001 0.02 0.01-0.02 <.001 -0.03 -0.07-0.00 .06 -0.04 -0.07--0.01 .02 
Ischemia 0.16 0.06-0.27 .002 0.16 0.04-0.27 .007 -1.10 -2.36-0.17 .09 -1.17 -2.43-0.09 .07 
PA*NA - - - - - - -0.00 -0.00-0.00 .09 -0.00 -0.00-0.00 .07 
PA* 
Ischemia 
- - - - - - 0.04 -0.01-0.08 .10 0.04 -0.00-0.08 .08 
NA* 
Ischemia 
- - - - - - 0.07 0.01-0.13 .03 0.07 0.01-0.13 .02 
PA*NA* 
Ischemia 
- - - - - - 
-0.00 -0.00-0.00 .09 -0.00 -0.00-0.00 .07 
 
β – Beta-estimate; 95%CI – 95% Confidence Intervals; † adjusted for age, sex, total exercise METS, prescription of anti-ischemic 
medications, and analgesic medication use 
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Table 4: Logistic regressions to examine the association between the presence of pain in ischemic and non-ischemic 
patients 
 
Non-ischemic patients only 
 Model 1 Model 2 † Model 3 † Model 4 † 
 
β OR OR 
95% 
CI 
p β OR OR  
95% 
CI 
p β β  95% 
CI 
p β β  
95% 
CI 
p 
PA 0.06 1.07 0.99 – 
1.14 
0.075 0.07 1.07 1.00 – 
1.15 
0.070 -0.21 -0.46 – 
0.04 
0.096 -0.23 -0.51 – 
0.02 
0.081 
NA 0.09 1.10 1.02 – 
1.18 
0.010 0.10 1.11 1.03 - 
1.20 
0.007 -0.32 -0.71 – 
0.07 
0.110 -0.35 -0.79 – 
0.04 
0.098 
PA*NA  - -  -  -  -  -  -  -  0.01 0 – 
0.03 
0.036 0.02 0 – 
0.03 
0.031 
Ischemic patients only 
 Model 1 Model 2 † Model 3 † Model 4 † 
 Β OR OR  
95% 
CI 
P Β OR OR 
95% 
CI 
p Β β  95% 
CI 
p Β β  
95% 
CI 
p 
PA 0.04 1.04 0.96 –
1.14 
0.31 0.06 1.07 0.96 – 
1.18 
0.22 0.09 -0.16 – 
0.34 
0.48 0.04 -0.26 – 
0.29 
0.79 
NA 0.13 1.14 1.03 - 
1.25 
0.008 0.13 1.13 1.02 – 
1.27 
0.026 0.19 -0.14 – 
0.52 
0.26 0.09 -0.32 – 
0.43 
0.63 
PA*NA  - -  -  - - - -  - -0.00 -0.01 – 
0.01 
0.69 0.00 -0.01 – 
0.02 
0.84 
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Note: β – Beta-estimate; 95%CI – 95% Confidence Intervals; † adjusted for age, sex, total exercise METS, prescription of 
anti-ischemic medications, and analgesic medication use. Sample sizes: Ischemic patients only (N=78); Non-ischemic 
patients only (N=172) 
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Figure 1: Recruitment of participants 
 
  
2138 patients presented to 
MHI, nuclear medicine depart.
1174 patients were 
approached
124 
patients 
approached 
were 
excluded
1050 approached patients 
were eligible 
143 patients 
declined 
907 patients accepted
246 completed the PANAS 
36 participation to another 
study
48 language criteria
4 chronic pain disorder
12 non-steroid anti-
inflammatory in the last 7 
days
11 major medical condition
13 analgesic the day of the 
stress test
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Figure 2: Chest pain reporting by positive affect in patients without ischemia (left) and patients with 
ischemia (right). Dashed line indicates Low NA, Solid line indicates High NA.  
 
 
Note: High PA: PANAS positive affect score > 33.9; Low PA: PANAS positive affect score < 26.1; High NA: PANAS negative 
affect score > 19.9; Low NA: PANAS negative affect score < 13.1. 
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